Genetics Program, Instituto Nacional de Câncer, Rio de Janeiro, 37 Andre Cavalcanti, Research Center, 4th Floor, 20231-050, Brazil.
Pathology Division, Instituto Nacional de Câncer, Rio de Janeiro, 156 Cordeiro da Graça, 156, 20220-400, Brazil.
Exp Eye Res. 2021 Oct;211:108753. doi: 10.1016/j.exer.2021.108753. Epub 2021 Aug 31.
Retinoblastoma is the most common malignant ocular tumor in children. Although RB1 alterations are most frequently involved in the etiology of retinoblastoma, candidate driver events and somatic alterations leading to cell transformation, tumor onset and progression remain poorly understood. In this study, we identified novel genomic alterations in tumors with a panel of 160 genes. Sanger sequencing and Multiplex Ligation-dependent Probe Amplification (MLPA) were initially performed for identifying patients without apparent RB1 alterations in blood DNA. Subsequently, NGS analyses of 24 paired (blood/tumor) samples of these patients were carried out for identifying somatic mutations and copy number variation in RB1 and other 159 genes. One novel pathogenic RB1 mutation and seven novel VUS were identified as well as 90 novel pathogenic mutations in 61 other genes. Twenty-three genes appeared exclusively mutated in tumors without altered RB1 alleles and three frequently affected biological pathways while five other tumors did not show pathogenic RB1 alterations or SNV/indels in 159 other genes. Curiously, deletion of GATA2, AKT1, ARID1A, DNMT3A, MAP2K2, MEN1, MTOR, PTCH1 and SUFU (in homo- or heterozygosity) were exclusively found in these tumors when compared to those with any pathogenic alterations, probably indicating genes that might be essential for the development of retinoblastoma regardless of a functional RB1. Identification of genes associated with retinoblastoma will contribute to understanding presently unknown aspects of this malignancy, which might be essential for its initiation and progression, as well as providing valuable molecular markers.
视网膜母细胞瘤是儿童中最常见的恶性眼部肿瘤。尽管 RB1 改变最常涉及视网膜母细胞瘤的病因,但导致细胞转化、肿瘤发生和进展的候选驱动事件和体细胞改变仍知之甚少。在这项研究中,我们使用 160 个基因的面板鉴定了肿瘤中的新的基因组改变。最初对血液 DNA 中无明显 RB1 改变的患者进行 Sanger 测序和多重连接依赖性探针扩增(MLPA)以鉴定。随后,对这些患者的 24 对(血液/肿瘤)样本进行了 NGS 分析,以鉴定 RB1 和其他 159 个基因中的体细胞突变和拷贝数变异。确定了一个新的致病性 RB1 突变和七个新的 VUS,以及其他 61 个基因中的 90 个新的致病性突变。在没有改变的 RB1 等位基因和三个经常受影响的生物学途径中,有 23 个基因仅在肿瘤中发生突变,而在其他 159 个基因中没有发现致病性 RB1 改变或 SNV/indels 的五个肿瘤则没有。奇怪的是,与具有任何致病性改变的肿瘤相比,这些肿瘤中仅发现了 GATA2、AKT1、ARID1A、DNMT3A、MAP2K2、MEN1、MTOR、PTCH1 和 SUFU(纯合或杂合)的缺失,这可能表明这些基因可能是视网膜母细胞瘤发生所必需的,而与 RB1 的功能无关。鉴定与视网膜母细胞瘤相关的基因将有助于了解这种恶性肿瘤目前未知的方面,这对于肿瘤的起始和进展可能是至关重要的,同时也为提供有价值的分子标志物。